| Name | Title | Contact Details |
|---|---|---|
Brian Kevany |
Chief Technical Officer | Profile |
Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines designed to induce a broad and robust protective immune response to both disease-relevant polysaccharides and disease-relevant proteins in a single vaccine. Affinivax designs each of its vaccine candidates to optimize the protective immune response to one or both of these antigens utilizing the distinctive plug-and-play nature of its proprietary MAPS™ technology platform, presenting the potential opportunity to make a significant step forward in addressing major healthcare challenges posed by novel and resistant infectious diseases. Affinivax was founded in 2014 with a seed investment from the Bill & Melinda Gates Foundation and an exclusive license to the MAPS technology from Boston Children`s Hospital.
The Pharmaceutical Product Development, LLC is a global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services.
BioTech Insight is a Pebble Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aspect DV is a Merrimack, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.